Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
An Update on EBV-related Cutaneous Lymphoproliferative Disorders: a Systematic Review.
Actas Dermosifiliogr
November 2024
Universidad de Zaragoza, Zaragoza, España; Servicio de Anatomía Patológica, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España.
Epstein Barr virus (EBV) positive B lymphoproliferative disorders (LPD) with cutaneous involvement include a series of rare entities that go from indolent processes to aggressive lymphomas. B-cell EBV+ LPD mainly affect immunocompromised patients while T-cell EBV+ LPD are more prevalent in specific geographic regions such as Asia, Central America, and South America. Since the latest WHO-EORTC classification of cutaneous lymphomas in 2018, significant changes have been included in the new classifications of hematological malignancies.
View Article and Find Full Text PDFClinical and Pathological Features of Primary Cutaneous Lymphomas in Nepal: A retrospective cohort study from a dermatology referral centre.
Kathmandu Univ Med J (KUMJ)
September 2024
Department of Dermatology and Venereology, Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Maharajgunj, Kathmandu, Nepal.
Article Synopsis
- In Nepal, a study looked at rare skin cancers called Primary cutaneous lymphomas to learn more about them.
- The researchers reviewed patient records from a dermatology center, finding 12 cases diagnosed between 2010 and 2020, mostly affecting older adults.
- They discovered that T-cell lymphomas were more common than B-cell lymphomas, and sadly, three patients died during the study period.
Epidemiological trends in cutaneous lymphomas in Greece.
Eur J Dermatol
December 2023
Hematopathology Department, "Evangelismos" General Hospital, Athens, Greece.
Article Synopsis
- Primary cutaneous lymphomas (PCLs) are a diverse group of skin-related non-Hodgkin lymphomas, primarily affecting T- or B-lymphocytes, and there's a lack of extensive data on their occurrence.
- A study in Attica, Greece, analyzed 1,189 patients diagnosed with PCL from 2009 to 2021, revealing a median diagnosis age of 62, with a higher prevalence in males, and an annual incidence rate (IR) of 2.2 per 100,000 individuals.
- The majority of cases were cutaneous T-cell lymphoma (CTCL) and specifically mycosis fungoides (MF), while the incidence rates increased until 2019 but
A Rare and Isolated Presentation of Primary Cutaneous Anaplastic Large Cell Lymphoma on the Breast.
Cureus
November 2023
Dermatology, Sheikh Khalifa Medical City, Abu Dhabi, ARE.
Article Synopsis
- Primary cutaneous anaplastic large-cell lymphoma (PC-ALCL) is a type of non-Hodgkin lymphoma that mainly affects the skin and makes up about 25% of cutaneous T-cell lymphomas.
- It usually appears as reddish-brown nodules on the skin, sometimes developing into ulcers, and while some cases may regress, complete resolution is rare.
- The text also describes a unique case of a 26-year-old woman with PC-ALCL who had no history of breast implants, highlighting the differences between ALK-positive and ALK-negative subtypes, particularly in breast presentations.
Prognostic factors for primary cutaneous anaplastic large-cell lymphoma: a multicentre retrospective study from Japan.
Br J Dermatol
October 2023
Department of Dermatology, International University of Health and Welfare, Chiba, Japan.
Article Synopsis
- DUSP22 rearrangement was found in 50% of cases of primary cutaneous anaplastic large-cell lymphoma (pcALCL), but not in lymphomatoid papulosis (LyP) or mycosis fungoides with large-cell transformation (MF-LCT).
- The study analyzed the clinical outcomes, survival rates, and immunohistochemical characteristics of patients diagnosed between 2000 and 2018 in Japan.
- No significant link was found between DUSP22 rearrangement and LEF1 expression pattern, but factors such as T3 stage and lower limb lesions were associated with poorer overall survival.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!